• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Dipeptidyl-peptidase IV inhibitor-associated bullous pemphigoid: A systematic review and meta-analysis.

作者信息

Kridin Khalaf, Cohen Arnon D

机构信息

Department of Dermatology, Rambam Health Care Campus, Haifa, Israel.

Department of Quality Measurements and Research, Chief Physician's Office, Clalit Health Services, Tel Aviv, Israel; Siaal Research Center for Family Medicine and Primary Care, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

出版信息

J Am Acad Dermatol. 2021 Aug;85(2):501-503. doi: 10.1016/j.jaad.2018.09.048. Epub 2018 Oct 5.

DOI:10.1016/j.jaad.2018.09.048
PMID:30296540
Abstract
摘要

相似文献

1
Dipeptidyl-peptidase IV inhibitor-associated bullous pemphigoid: A systematic review and meta-analysis.二肽基肽酶IV抑制剂相关的大疱性类天疱疮：一项系统评价和荟萃分析。
J Am Acad Dermatol. 2021 Aug;85(2):501-503. doi: 10.1016/j.jaad.2018.09.048. Epub 2018 Oct 5.
2
Bullous pemphigoid and DPP4 inhibitors.
Med Clin (Barc). 2019 Nov 15;153(9):368-371. doi: 10.1016/j.medcli.2019.04.031. Epub 2019 Jul 18.
3
Unique clinical and serological features of bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors.与二肽基肽酶-4抑制剂相关的大疱性类天疱疮的独特临床和血清学特征。
Br J Dermatol. 2018 Jun;178(6):1462-1463. doi: 10.1111/bjd.16479. Epub 2018 Apr 16.
4
Bullous pemphigoid and dipeptidyl peptidase IV inhibitors: a case-noncase study in the French Pharmacovigilance Database.大疱性类天疱疮与二肽基肽酶-4 抑制剂：法国药物警戒数据库中的病例对照研究。
Br J Dermatol. 2016 Aug;175(2):296-301. doi: 10.1111/bjd.14601. Epub 2016 Jul 19.
5
Bullous pemphigoid with dipeptidyl peptidase-4 inhibitors: Clinical features and pathophysiology.伴有二肽基肽酶-4 抑制剂的大疱性类天疱疮：临床特征和发病机制。
J Diabetes Investig. 2019 Sep;10(5):1168-1170. doi: 10.1111/jdi.13060. Epub 2019 May 14.
6
Three Cases of Bullous Pemphigoid Associated with Dipeptidyl Peptidase-4 Inhibitors - One due to Linagliptin.三例与二肽基肽酶-4抑制剂相关的大疱性类天疱疮——其中一例由利格列汀引起。
Dermatology. 2016;232(2):249-53. doi: 10.1159/000443330. Epub 2016 Jan 28.
7
Linagliptin-associated bullous pemphigoid treated with rituximab.用利妥昔单抗治疗的与利格列汀相关的大疱性类天疱疮。
BMJ Case Rep. 2019 Sep 30;12(9):e229902. doi: 10.1136/bcr-2019-229902.
8
Gliptin-Induced Bullous Pemphigoid: Canadian Case Series of 10 Patients.Gliptin 诱导性大疱性类天疱疮：10 例加拿大患者的病例系列。
J Cutan Med Surg. 2021 Mar-Apr;25(2):163-168. doi: 10.1177/1203475420972349. Epub 2020 Nov 11.
9
The association of bullous pemphigoid with dipeptidyl-peptidase 4 inhibitors: a ten-year prospective observational study.大疱性类天疱疮与二肽基肽酶 4 抑制剂的相关性：一项十年前瞻性观察研究。
BMC Endocr Disord. 2021 Feb 11;21(1):23. doi: 10.1186/s12902-021-00689-7.
10
Association of Bullous Pemphigoid With Dipeptidyl-Peptidase 4 Inhibitors in Patients With Diabetes: Estimating the Risk of the New Agents and Characterizing the Patients.糖尿病患者中疱疹样天疱疮与二肽基肽酶-4 抑制剂的关联：评估新型药物的风险并描述患者特征。
JAMA Dermatol. 2018 Oct 1;154(10):1152-1158. doi: 10.1001/jamadermatol.2018.2352.

引用本文的文献

1
GLP-1 Receptor Agonists, DPP-4 Inhibitors and the Skin-Diabetes Meets Dermatology: A Brief Narrative Review.胰高血糖素样肽-1受体激动剂、二肽基肽酶-4抑制剂与皮肤——糖尿病与皮肤病学的交汇：一篇简要叙述性综述
Adv Ther. 2025 Jun 5. doi: 10.1007/s12325-025-03257-w.
2
Lymphocyte Transformation Tests and Patch Tests to Identify Drugs Potentially Associated With Bullous Pemphigoid Development.淋巴细胞转化试验和斑贴试验以鉴定可能与大疱性类天疱疮发生相关的药物。
Int J Dermatol. 2025 Sep;64(9):1636-1643. doi: 10.1111/ijd.17849. Epub 2025 May 15.
3
Identification of Risk Factors for Gliptin-associated Bullous Pemphigoid among Diabetic Patients.
识别糖尿病患者中与格列汀相关的大疱性类天疱疮的风险因素。
Acta Derm Venereol. 2024 Apr 4;104:adv26663. doi: 10.2340/actadv.v104.26663.
4
From Molecular Insights to Clinical Perspectives in Drug-Associated Bullous Pemphigoid.从药物相关性大疱性表皮松解症的分子见解到临床观点。
Int J Mol Sci. 2023 Nov 26;24(23):16786. doi: 10.3390/ijms242316786.
5
Role of Human Leukocyte Antigen Class II in Antibody-Mediated Skin Disorders.人类白细胞抗原 II 类在抗体介导的皮肤疾病中的作用。
Medicina (Kaunas). 2023 Nov 4;59(11):1950. doi: 10.3390/medicina59111950.
6
Autoimmune bullous dermatoses in cancer patients treated by immunotherapy: a literature review and Italian multicentric experience.接受免疫治疗的癌症患者中的自身免疫性大疱性皮肤病：文献综述及意大利多中心经验
Front Med (Lausanne). 2023 Jul 20;10:1208418. doi: 10.3389/fmed.2023.1208418. eCollection 2023.
7
The effect of dipeptidyl peptidase-4 inhibitor on incidence and clinical course in bullous pemphigoid patients in a tertiary medical center.三级医疗中心中双肽基肽酶-4抑制剂对大疱性类天疱疮患者发病率及临床病程的影响
Kaohsiung J Med Sci. 2023 Oct;39(10):1038-1044. doi: 10.1002/kjm2.12731. Epub 2023 Aug 2.
8
Bullous Pemphigoid and Human Leukocyte Antigen (HLA)-DQA1: A Systematic Review.大疱性类天疱疮与人类白细胞抗原（HLA）-DQA1：一项系统评价
Cureus. 2023 Jun 3;15(6):e39923. doi: 10.7759/cureus.39923. eCollection 2023 Jun.
9
Treatment of Diabetes in Bullous Pemphigoid Patients: Where Do We Stand?大疱性类天疱疮患者糖尿病的治疗：我们目前的状况如何？
Dermatol Pract Concept. 2023 Jan 1;13(1):e2023063. doi: 10.5826/dpc.1301a63.
10
Researching trends in pemphigoid diseases: A bibliometric study of the top 100 most cited publications.类天疱疮疾病研究趋势：对100篇被引频次最高的出版物的文献计量学研究
Front Med (Lausanne). 2023 Jan 9;9:1088083. doi: 10.3389/fmed.2022.1088083. eCollection 2022.